The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work ...

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine segment. See why the stock is a Buy.

Our team is working diligently to resolve the issue. ... which is more than double the S&P 500's performance over the same time frame. ... GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report.

GSK plc's stock price has significantly outperformed the healthcare sector this year, supported by its healthy Q1 2025 numbers. Learn more about GSK stock here.

In May, biotech iTeos Therapeutics decided to close down after being abandoned by GSK over the disappointing mid-stage ...

GSK is scheduled to report results for the first quarter on Wednesday. Here is what to know. SALES FORECAST: The British pharmaceutical giant is expected to report sales for the period of 7.42 ...

GSK and Spero ended a Phase 3 trial early meeting efficacy goals in cUTIs, ... Spero’s stock price was up 245.89% at last check Wednesday following the news.

Analysts are also bullish on the stock because of the notable performance of its specialty medicine segment, which is GSK plc’s (NYSE:GSK) largest business area.

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several ...